Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of bacillus coagulans in preparing medicine for treating inflammatory bowel disease

A technology for Bacillus coagulans and inflammatory bowel disease, applied in the field of biological medicine, can solve the problems of low curative effect, secondary infection, large adverse reactions, etc., to enhance mucosal immune function, prevent the recurrence of inflammation, and improve disease resistance. Effect

Inactive Publication Date: 2011-06-15
QINGDAO EASTSEA PHARMA +1
View PDF0 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The traditional treatment drugs for IBD include aminosalicylic acid, antibiotics and corticosteroids, etc. Because of their low curative effect and large adverse reactions, patients often cannot tolerate them, resulting in certain limitations in clinical application.
The application of immunosuppressants such as azathioprine (AZA), 6-mercaptopurine (6-MP), methotrexate (MTX) and cyclosporine can make most IBD patients, especially intractable cases, obtain a certain degree of clinical However, these immunosuppressants still have the disadvantages of high toxicity, poor selectivity, and the possibility of secondary infection and teratogenicity, so the clinical application is still not ideal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bacillus coagulans in preparing medicine for treating inflammatory bowel disease
  • Application of bacillus coagulans in preparing medicine for treating inflammatory bowel disease
  • Application of bacillus coagulans in preparing medicine for treating inflammatory bowel disease

Examples

Experimental program
Comparison scheme
Effect test

preparation Embodiment 1

[0021] Pharmaceutical Preparation Example 1. Preparation of live Clostridium butyricum bacteria powder:

[0022] Take a tube of live Clostridium butyricum strain and dissolve it in a sterilized 100ml Erlenmeyer flask containing 10ml of saline and glass beads. Activate for 10 minutes. Use a 1ml sterile straw to inoculate 1ml of bacterial suspension and inoculate a 50ml flask. In a 250ml Erlenmeyer flask with enrichment medium, place it in a rocking bed at 37°C with constant temperature shaking (190rpm) for 24 hours, transfer to a 2500ml baffle flask containing 450ml of amplification medium, culture at 37°C with constant temperature shaking for 24 hours, microscopic examination After there is no bacteria, transfer to the seed tank with 4.5L expansion medium, anaerobic culture (aeration volume 3:1) for 24 hours, and then transfer to the fermentation tank with 45L fermentation medium after microscopic inspection without bacteria During anaerobic culture at 37°C for 24 hours, the spor...

preparation Embodiment 2

[0023] Pharmaceutical preparation example 2. Preparation of live Clostridium butyricum capsules

[0024] Composition% (weight)

[0025] Clostridium butyricum live bacteria powder 20.00 copies

[0026] Microcrystalline cellulose 40.00 parts

[0027] Glucose 40.00 parts

[0028] Mix well in groups 1 to 3 of the above components, and then use conventional capsule filling technology to form capsules according to the unit dose.

experiment example 1

[0029] Basic experimental example 1. Therapeutic effect of Clostridium butyricum and Bacillus coagulans on immune rats with inflammatory bowel disease

[0030] 1 Experimental materials and methods

[0031] 1.1 Experimental animals: Male SD rats, 180-220g, purchased from Weitong Lihua Experimental Animal Center, clean grade, certificate number: SCXP (Beijing) (2002)-0003.

[0032] 1.2 Experimental drugs: Mesalazine (200mg / ml); Clostridium butyricum (CGMCC No.0313.1 strain, 10 8 CFU / ml), Bacillus coagulans (CGMCC No. 1207 strain, 10 8 CFU / ml) was provided by Qingdao Donghai Pharmaceutical Co., Ltd.

[0033] 1.3 Experimental reagents: Freund's complete adjuvant (sigma), MTT (sigma), concanavalin (ConA) (Sigma); lipopolysaccharide (LPS) (Sigma); MTT (Sigma), purchased from Beijing Shubowei Chemical Instrument Co., Ltd.; 1640 culture medium (Gibco); bovine colon mucosal protein freeze-dried powder (homemade); IL-8 ELISA kit (BD); TNFα ELISA kit (Ebioscience); rat IgG reference serum; rabbi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses new medical application of bacillus coagulans, particularly relates to application of the bacillus coagulans in preparing a medicine for treating an inflammatory bowel disease. The inflammatory bowel disease refers to ulcerative colitis and a crohn disease; the bacillus coagulans is selected but not limited from the bacillus coagulans preserved in the The China General Microbiological Culture Collection Center (CGMCC) with the preservation number of 1207. The bacillus coagulans has outstanding treatment effect when being used for treating the crohn disease as a medical active component and belongs to the field of biological medicines.

Description

[0001] Description [0002] This application is a divisional application. The original application date: January 29, 2007, the original application number: 2007100026923, the original invention names: Clostridium butyricum and Bacillus coagulans application in the preparation of drugs for the treatment of inflammatory bowel disease. Technical field [0003] The present invention relates to a new drug application of Clostridium butyricum and Bacillus coagulans, and specifically relates to Clostridium butyricum and Bacillus coagulans alone or in combination as active ingredients in the preparation of drugs for the treatment of inflammatory bowel disease, namely ulcerative colitis and Crohn’s disease The application in the field belongs to the field of biological medicine. Background technique [0004] Inflammatory bowel disease (IBD) is the collective term for Ulcerative colitis (UC) and Crohn’s disease (CD). Traditional medicine believes that the cause is unknown. Ulcerative colitis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/74A61P1/00A61P29/00A61K35/742
Inventor 崔云龙
Owner QINGDAO EASTSEA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com